INmune Bio (NASDAQ:INMB) Now Covered by Raymond James

Raymond James started coverage on shares of INmune Bio (NASDAQ:INMB) in a research report issued on Friday, MarketBeat Ratings reports. The firm set an “outperform” rating and a $18.00 price target on the stock. Raymond James’ price objective indicates a potential upside of 244.83% from the company’s previous close.

Separately, Scotiabank started coverage on shares of INmune Bio in a research note on Thursday, August 22nd. They issued a “sector outperform” rating and a $22.00 price objective on the stock.

INmune Bio Price Performance

Shares of INmune Bio stock opened at $5.22 on Friday. The business has a 50-day simple moving average of $6.73 and a 200 day simple moving average of $8.79. INmune Bio has a one year low of $4.81 and a one year high of $14.74. The firm has a market capitalization of $103.26 million, a price-to-earnings ratio of -2.72 and a beta of 1.86.

INmune Bio (NASDAQ:INMB) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.13. INmune Bio had a negative return on equity of 103.56% and a negative net margin of 26,333.59%.

Insider Activity at INmune Bio

In related news, CFO David J. Moss acquired 7,690 shares of the company’s stock in a transaction on Thursday, September 12th. The shares were acquired at an average cost of $6.38 per share, for a total transaction of $49,062.20. Following the purchase, the chief financial officer now owns 1,275,869 shares in the company, valued at $8,140,044.22. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CEO Raymond Joseph Tesi acquired 15,380 shares of the firm’s stock in a transaction on Thursday, September 12th. The stock was purchased at an average price of $6.38 per share, for a total transaction of $98,124.40. Following the purchase, the chief executive officer now owns 1,554,106 shares in the company, valued at approximately $9,915,196.28. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO David J. Moss bought 7,690 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was acquired at an average price of $6.38 per share, for a total transaction of $49,062.20. Following the purchase, the chief financial officer now directly owns 1,275,869 shares in the company, valued at $8,140,044.22. The disclosure for this purchase can be found here. 35.20% of the stock is owned by insiders.

Institutional Trading of INmune Bio

A number of hedge funds have recently bought and sold shares of INMB. Rhumbline Advisers purchased a new stake in shares of INmune Bio during the 2nd quarter valued at $121,000. Fermata Advisors LLC raised its position in INmune Bio by 6.9% in the first quarter. Fermata Advisors LLC now owns 31,451 shares of the company’s stock worth $370,000 after acquiring an additional 2,025 shares during the period. Westside Investment Management Inc. boosted its stake in INmune Bio by 31.8% in the second quarter. Westside Investment Management Inc. now owns 45,340 shares of the company’s stock valued at $400,000 after acquiring an additional 10,950 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of INmune Bio by 124.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock valued at $517,000 after acquiring an additional 32,511 shares during the period. Finally, Marshall Wace LLP increased its stake in shares of INmune Bio by 332.1% during the 2nd quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock worth $1,022,000 after purchasing an additional 89,091 shares during the last quarter. 12.72% of the stock is currently owned by institutional investors.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.